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ABSTRACT
Deoxyribonucleic acid (DNA) forms the blueprint of life, wherein the genetic infor-
mation required for the growth and development of organism is stored. Epigenetics
deals with the heritable phenotypic changes in the organism without altering the
DNA sequence. It serves as a mediator between environment and genomes and
controls which genes are turned on or off. The most studied epigenetic modification
is the DNA methylation - the addition of a methyl group to the cytosine base of the
DNA. Methylation patterns are crucial for the normal functioning of an organism
and are susceptible to change owing to environmental changes, disease progression,
and aging. Therefore, methylation patterns can be used as a biomarker indicating
the normal biological process, disease progress, and prognosis. The current thesis
aims to explore the role of DNA methylation in various human biological condi-
tions and to predict biologically driven biomarker candidates by employing various
computational and statistical methods.
In the first part of the thesis, three biological studies were considered to predict
the DNA methylation-based biomarkers. The first study included several rare
healthy tissues, whereas the following one is related to menstrual cycle-specific
methylation patterns in endometriosis (a gynecological disease associated with
endometrial dysfunction) patients and healthy controls. Subsequently, the final
study pertains to the identification of methylation changes during the transition
from pre-receptive to the receptive endometrium. A few of the methods used to
achieve the aforementioned aim include customized data processing (normalization
and batch effect correction), clustering analysis, differential methylation analysis,
gene enrichment analysis, and integration with gene expression data combined
with powerful data visualization approaches.
After predicting the DNA methylation biomarkers in selected biological condi-
tions, we aimed to understand the applicability of DNA methylation patterns as
a biomarker to predict cancer patients’ survival in different cancer types. DNA
methylation and clinical data relevant to this study were identified from “The
Cancer Genome Atlas” (TCGA) database. In order to assist the scientific commu-
nity to explore methylation-based prognostic biomarkers, MethSurv a web tool
was developed. The technical features in the MethSurv include Cox-proportional
hazard model fitting for understanding patients’ survival, clustering and principal
component analysis (PCA). The developed tool remains a prominent platform to
integrate the statistical and computational tools on the DNA methylation data from
TCGA. Further, it helps in facilitating the initial assessment of methylation-based
cancer biomarkers.
In conclusion, the studies included in this thesis develop and combine numerous
bioinformatics and statistical methods enabling a rapid and cost-effective way to
identify DNA methylation patterns as a potential biomarker candidate.
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INTRODUCTION
Epigenetics can be formally defined as "the study of heritable phenotype changes
that do not involve alterations in the DNA sequence" (Dupont et al., 2009). DNA
methylation patterns are known to control the regulation of gene expression through
the epigenetic mechanism. Moreover, methylation patterns are associated with
various biological processes such as embryonic development, genomic imprinting,
and X-chromosome inactivation. Certain genomic methylation patterns are known
to be associated with diseases such as diabetes, neurological disorders, and cancer
development. Therefore, DNA methylation patterns are proposed as a biomarker
candidate that indicates the normal biological process as well as disease progression.
High-throughput technologies, such as microarrays or next-generation sequencing
(NGS), provide methylation profiles on a genomic scale. Methylation microarrays,
primarily the Illumina HumanMethylation450K (HM450K) array (Illumina Inc.,
San Diego, CA, USA), have been a popular choice owing to their cost-effectiveness
and quantification in well-characterized regions of the human genome.
The current thesis aims to identify DNA methylation patterns as a potential
biomarker candidate in healthy as well as disease states with the use of HM450K
methylation data, by utilizing various computational and statistical approaches.
The first part of the thesis focuses on identifying DNA methylation biomarker
candidates in healthy and diseased tissues using bioinformatic methods. For this,
we utilized the methylation data generated from different project partners, which
resulted in Publications I, II and III. To elaborate, in Publication I, using bioinfor-
matic methods such as clustering analysis, linear regression, correlation analysis,
and integration with gene expression data, we showed that methylation patterns
can be used for tissue classification. On the other hand, in Publication II, the main
analytical problem was the discovery and management of the batch effect, since
the methylation data were generated from different labs and cohorts. Applying
the Empirical Bayes method, the said effect was successfully corrected. Further,
the methylation markers in endometriosis pathogenesis were evaluated using cus-
tomized workflow from Publication I. In Publication III, bioinformatic methods
obtained from the previous publications were further improved and tailored to iden-
tify methylation biomarkers associated with endometrial receptivity. Additionally,
multiple differential methylation analysis methods were utilized and the overlap of
the same were applied to identify biomarkers with higher confidence.
The second aim of this thesis was to identify survival biomarkers in different
cancer types. For this purpose, methylation and clinical data were utilized from
the TCGA consortium, which are described in Publication IV. Here, we developed
an intuitive and exploratory web tool to assist scientists lacking bioinformatics,
computational, or statistical skills. Furthermore, we processed multiple methylation
and clinical datasets generated from different cancer types. The created web tool
has multiple functionalities including analysis of methylation patterns in relation
to patient survival in cancer types, visualization of methylation patterns, perform
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cluster analysis, and the most important biomarkers for each type of cancer.
The current thesis is structured as follows:
In its first part, we provide the biological background on DNA methylation,
summarize the methods used to measure methylation levels, and emphasize the
role of methylation in human health and disease. Subsequently, we summarize
different bioinformatic methods applied to further explore methylation biomarkers
used in different studies included in this thesis (Lokk et al., 2014; Saare et al.,
2016; Kukushkina et al., 2017; Modhukur et al., 2017) with a brief description of
context-based methods. Chapters II–V summarize the publications included in
this thesis. Finally, the thesis ends with the discussion highlighting strengthens
and weakness of the study design, future perspectives and concluding remarks.
Reprints of the Publications I–IV are included at the end of this thesis.
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1. PRELIMINARIES
This chapter introduces some of the biological background as well as the bioinfor-
matic methods that are necessary to understand the research related contribution of
this thesis.
1.1. Biological background
1.1.1. The human genome and the epigenome
The hereditary information of living beings is stored and preserved by the DNA,
which comprises four chemical bases, namely adenine (A), guanine (G), cytosine
(C), and thymine (T), and is packaged inside the nucleus of the cell. The human
genome consists of approximately 3.2 billion base pairs (bp). Furthermore, the
DNA is compacted into discrete sections of different lengths called chromosomes.
Humans have 46 chromosomes, among which 22 pairs are termed as autosomes,
while the 23rd pair carries the sex chromosomes (X and Y). Moreover, the cell
nucleus comprises two copies of chromosomes, each of which is inherited from
the parents. The process through which it makes two identical copies of itself is
called DNA replication. The flow of genetic information (central dogma) takes
place from DNA to ribonucleic acid (RNA) (transcription) and subsequently from
RNA to protein (termed as translation). This process occurs in all living organisms
and forms the basis for biological inheritance. The genetic information derived
from the DNA is read and processed in individual cell and tissue types differently.
Epigenetic modification acts as an information control that governs the way in
which DNA can be processed. Epigenetic modifications include DNA methylation,
histone modifications, and RNA modifications that control the cellular phenotype
by regulating the gene expression (Zaidi et al., 2010) (Figure 1). DNA methy-
lation involves the addition of methyl group to the DNA. In the case of histone
modification, histone proteins (which packages the DNA in nucleosome) are prone
to various types of chemical modifications such as methylation and acetylation
(Figure 1).
1.1.2. DNA methylation
Methylation that involves the addition of the methyl group at the C-5 of cytosine,
resulting in 5mc (See Figure 2), termed as CpG methylation (where p denotes the
phosphodiester bond). Methylation can also take place in the non-CpG context
such as such as CpA, CpT, and CpC (Jang et al., 2017). In addition, hydroxymethy-
lation replaces the C5-position in cytosine by a hydroxy methyl group (hm5C).
The highest level of hydroxy methylation is known to occur in the brain (Lister
et al., 2013; Guibert and Weber, 2013).
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Figure 1. Epigenetic modifications. This figure depicts epigenetic modifications such as
DNA methylation and histone modifications taking place in the chromosome of the cell.
This figure has been adapted from Zaidi et al. (2010) and reprinted with permission from
American Society for Microbiology.
Figure 2. DNA methylation. The figure shows a methyl group (CH3) added to the 5th
position of cytosine through DNA methyltransferase enzymes (DNMT), creating 5mc.
This figure has been adapted from Wikimedia (2016), distributed under a CC BY-SA 4.0
license.
1.1.3. DNA methylation in health and disease
In this section, we provide a short overview of DNA methylation’s role in health
and disease, with a focus on the biological studies regarded in the current thesis.
Tissue-specific DNA methylation patterns. DNA methylation patterns are essen-
tial to direct the cells towards their respective lineages and ultimately leading to the
development of a mammalian organism (Okano et al., 1999; Messerschmidt et al.,
2014). Moreover, DNA methylation changes play a crucial role in establishing
cell type or tissue-specific epigenomes (Reik, 2007). Furthermore, methylation
patterns are suggested to be highly variable among different tissues of the same
individual, in comparison to different organisms concerning the same tissue.
13
Age-related methylation. Aging is a natural process in human life representing
the accumulation of changes over time (Bowen and Atwood, 2004). However,
aging is also considered as a disease according to Bulterijs et al. (2015). Several
studies suggested a strong correlation between age and DNA methylation levels
(Jung and Pfeifer, 2015). Age-related methylation changes are partly caused by
environmental changes (Gabbianelli and Damiani, 2018). Moreover, age-related
methylation changes are also suggested to contribute for gene expression changes in
diseases, particularly in type 2 diabetes (Nilsson et al., 2014) linked with epigenetic
aging in alcohol dependence (Rosen et al., 2018).
Tissue-specific methylation changes are suggested to be a useful tool for bio-
logical age prediction, also known as Hovarth’s epigenetic clock (Horvath, 2013).
Briefly, an age estimator was developed using 8,000 samples from 82 Illumina
DNA methylation array datasets, containing 51 healthy tissues and cell types. In
Hovarth’s clock, set of 353 CpGs were identified as the age stimulator within the
organism. However, Hovarth’s clock is not accurate for tissues which are subject
to hormonal changes such as endometrium or breast tissue (Olesen et al., 2018).
Therefore, more studies and pipelines are needed to understand the methylome
changes in such tissues.
DNA methylation patterns in diseases. DNA methylation plays a vital role in ge-
nomic imprinting, which causes genes to be expressed in a parent-of-origin- specific
manner (Reik et al., 1987; Sapienza et al., 1987; Hadchouel et al., 1987).Moreover,
normal methylation patterns are essential to control the gene expression of the
paternal and maternal alleles of imprinted genes (Li et al., 1993). Gain or loss of
methylation at imprinting-control regions may result in several imprinting disorders
such as Prader-Willi syndrome, Angelman syndrome and Beckwith-Wiedemann
syndrome (Henry et al., 1991).
Autoimmune disease is a condition which arises when the body’s immune
system attacks healthy cells. Aberrant DNA methylation changes are linked to
autoimmune diseases and are suggested to be caused by the strong interplay
between environmental factors, genetic variants, drugs, and miRNAs, resulting
in aberrant DNA methylation (Sun et al., 2016). A genome-wide case-control
study by Ellis et al. (2012) suggested differential T cell DNA methylation is an
essential feature in juvenile idiopathic arthritis. Likewise, Cai et al. (2017) reported
hypomethylation in the promoter regions of IL-6 gene observed in the peripheral
blood. Furthermore, Meng et al. (2017) showed that methylation patterns acts
as a link between genetic and environmental factors by mediating the interaction
between the genotype and smoking behavior in rheumatoid arthritis.
DNA methylation patterns are important for normal brain functions (Weng et al.,
2013). Research in the recent decades suggested a link between DNA methylation
and neurodegenerative diseases, which features the progressive loss of neurons (Lu
et al., 2013). It has been suggested that environmental factors such as exposure
to pesticide during mothers’ pregnancy may cause DNA methylation changes in
placental tissue, leading to higher risk for autism spectrum disorder for the child
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(Schmidt et al., 2016). Further, COMT gene was shown to be hypomethylated in
schizophrenia patients when compared to healthy controls, observed in peripheral
blood. It has also been shown that SNCA and PARK2 genes exhibits decreased
levels of methylation in the early onset of Parkinson’s disease (Eryilmaz et al.,
2017).
DNA methylation in the endometrium. The endometrium (inner lining of the
uterus) includes epithelial, stromal, and endothelial cells. It is controlled by a
series of hormones and undergoes cyclic as well as structural changes during every
menstrual cycle (which lasts for 28 days on an average during reproductive years)
(Caplakova et al., 2016). A menstrual cycle is divided into three main phases in the
following chronological order: menstrual, proliferative, and secretory (Figure 3).
Figure 3. Structural changes in endometrium during a normal menstrual cycle
(about 28 days). Menstrual cycle days (ranging about 28 days) are represented by numbers
and the respective menstrual phase is shown below. Figure modified from Wikimedia
(2004), distributed under a CC-BY 2.0 license.
During the proliferative phase of normal endometrium, estrogen controls the
growth of epithelial and stromal cells (Baca-García et al., 1998; Caplakova et al.,
2016), while the secretory phase is controlled by the hormone progesterone
(Caplakova et al., 2016). Furthermore, methylation changes in healthy human
cycling endometrial tissue has been studied byHoushdaran et al. (2014), and the
substantial changes in DNA methylation are reported to occur between prolifera-
tive and mid-secretory phase wherein the endometrial tissue reaches its maximal
thickness and is ready for embryo implantation (Houshdaran et al., 2014).
Moreover, methylation changes are also hypothesized in endometriosis disease
progression. Endometriosis is a gynecological disease, wherein the endometrial-
like tissues grows outside the uterine cavity (Guo, 2009). Several studies conducted
in the past decades suggested endometriosis as the hormonal and even genetic
disease (Guo, 2009). However, epigenetic changes are also assosiated with the
endometriosis. Specifically, DNA methylation patterns are shown to regulate the
gene expression, thereby playing a possible role in endometriosis pathogenesis.
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DNA methylation in cancer. Cancer is a complex disease that remains a major
public health concern. Cancer development is known to be influenced by both
epigenetic and genetic alterations (Feinberg et al., 2006; Jones and Baylin, 2007). In
particular, abnormal methylation patterns form the hallmark of cancer development.
Cancer cells are known to exhibit genome-wide hypomethylation and site-specific
CpG island promoter hypermethylation (Rodríguez-Paredes and Esteller, 2011;
Kulis and Esteller, 2010). In cancer cells, DNA hypomethylation is known to occur
in multiple genomic loci including repetitive genomic elements, retrotransposons,
satellite sequences, and so on, leading to overall genomic instability (Rodríguez-
Paredes and Esteller, 2011; Kulis and Esteller, 2010).
1.1.4. DNA methylation biomarkers
A biomarker may refer to the characteristic feature of biological processe(s), which
can be quantifiable (Strimbu and Tavel, 2010). According to the National Institutes
of Health Biomarkers Definitions Working Group, biomarkers can be defined
as “a characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention.”, (Group et al., 2001). In the previous section, we
briefly explained the way DNA methylation patterns are associated with several
normal biological processes as well as disease progression, contributing towards a
possible biomarker candidate. In this thesis, we identified the biomarker potential
of DNA methylation using different biological conditions.
1.1.5. Profiling of DNA methylation
The advent of NGS and microarray technologies allows us to assess DNA methyla-
tion changes in different biological conditions on a scale at the genome-wide level
(Yong et al., 2016). The experimental methods to profile genome-wide methylation
include the following:
• Enrichment based methods;
• Bisulphite sequencing and
• Bisulphite microarrays
In an enrichment based method, methylated or unmethylated DNA fragments
are enriched using several molecules such as methyl-CpG-binding domain (MBD)
proteins, restriction antibodies or methylation specific antibodies in a DNA library
(Bock, 2012). The enrichment step is followed by quantification using the NGS
approach.
In bisulphite sequencing based-approach, the DNA is treated with sodium bisul-
phite which introduces mutations in unmethylated C’s and are further quantified
using NGS based methods (Bock, 2012).
On the other hand, in bisulphite microarrays, bisulphite treatment is combined
with microarrays, which enables measuring DNA methylation levels at a prese-
lected fraction of Cs throughout the genome. Moreover, the said microarrays are
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cheaper in terms of their cost per sample compared to the whole genome bisulphite
sequencing approach (Bock, 2012). One of the major drawback in using microar-
rays is that it is not possible to discriminate between 5mC and 5hmC (Bock, 2012).
Furthermore, the HM450K array is based on bisulphite conversion where bisul-
phite treatment converts unmethylated cytosines into thymines, while methylated
cytosines remain unaffected (Frommer et al., 1992). In bisulphite microarrays,
a set of probes are predesigned for bisulphite conversion. The HM450K array
profiles 485,577 probes of which 482,421 CpG sites, 3091 non-CpG sites and 65
randomly designed single nucleotide polymorphism (SNP) sites (Bibikova et al.,
2011), serve as a part of experimental control. Additionally, the said array includes
21,231 genes (99 % RefSeq genes), 26,658 CpG islands (CGI, defined as >200 bp
long, >50% GC composition and an observed-to-expected CpG ratio greater than
0.6 (Gardiner-Garden and Frommer, 1987) (96% CGIs), 26,249 CGI shores (0-2
kb from CGI) and 24,018 CGI shelves(2-4 kb from CGI) (Bibikova et al., 2011).
Further, probes covering gene-centric regions were further targeted across multiple
sub-regions. To summarize, promoter regions were divided into TSS200 (region
from the transcription start site [TSS] to -200 nucleotides upstream of the TSS)
and TSS1500 (covering -200 to -1500 nucleotides upstream of TSS) respectively)
(Bibikova et al., 2011). In addition, 5’ and 3’ (Untranslated region) UTR, first exon
and gene body were also targeted (Bibikova et al., 2011). Figure 4 depicts the
gene-centric and CGI regions covered in the HM450K array. A brief summary
of methylation based arrays available from Illumina is presented in Table 1; the
current thesis utilizes DNA methylation data profiled using the HM450K array.
Figure 4. An illustrative representation of the gene-centric and CGI regions covered
in the HM450K array. TSS: Transcription start site; UTR: Untranslated region. This
figure has been redraw from (Huang et al., 2014).
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Technique Release date Nr. Probes Nr. Studies Nr. Samples
HM27K April 27, 2009 27,578 341 18,858
HM450K May 13, 2011 485,577 1,223 86,637
EPIC Nov 16, 2015 850,000 103 3899
Table 1. Details of the methylation based arrays published by Illumina. Release date,
number of samples, and number of studies are retrieved from GEO database, as on 11
April 2019 (Edgar et al., 2002). HM27K: HumanMethylation27 BeadChip; HM450K:
HumanMethylation450K BeadChip; EPIC: Infinium MethylationEPIC Kit.
1.2. Bioinformatics methods
In this section, a general overview of the analytical pipeline (See Figure 5)
utilized in this thesis will be provided. These methods are most suited for the
analysis of the HM450K array and can be tailored for the analysis of other genome-
wide methylation quantification methods described in Section 1.1.5. Extensive
data processing steps such as quality control, normalization, and batch effect
correction are required to address biological questions. Following the quality
control and normalization procedures, statistical methods including exploratory
analysis, such as data clustering, correlation analysis, and confirmatory analysis
including differential methylation analysis, have been performed for an overall
interpretation of the data obtained. The details pertaining to these methods will be
discussed in the following section.
1.2.1. Quality control and normalization
Quality control of methylation data is necessary to ensure reliable and high quality
data necessary for subsequent analysis (Cazaly et al., 2016). The main steps of the
quality control procedure have been explained below.
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Figure 5. A flow diagram illustrating anaytical pipeline utilized in the current thesis.
DMP: Differentially methylated position; DMR: Differentially methylated region.
Raw data processing. Methylation measurement data are usually presented
in a binary format called IDAT files, which contain intensity signals from the
red (methylated signal) and green channels (unmethylated signal). These IDAT
files contains intensity signals from the red (methylated signal) and green channel
(unmethylated signal), respectively (Dedeurwaerder et al., 2013). Such IDAT
files can be conveniently loaded in the R programming environment (Team, 2017)
using any of the R bioconductor packages which includes minfi (Aryee et al.,
2014), methylumi (Davis et al., 2015) and ChAMP (Morris and Beck, 2015). The
methylation levels for every CpG are represented by the β value, which can be
calculated as follows:
β =
max(m,0)
max(m,0)+max(u,0)+α
(1.1)
In this equation, m and u denotes methylated and unmethylated signal, respec-
tively. A β value of 0 denote an unmethylated CpG, while the β value 1 denote
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a fully methylated CpG site. Additionally, the offset α (usually set equal to 100)
enables the stabilization of beta values when both m and u are smaller (Du et al.,
2010). Alternatively, methylation values can also be represented in M values, as
described by the following equation:
M = log2
(
max(m,0)+α
max(u,0)+α
)
(1.2)
Based on the aforementioned equations, the relationship between β and M (Du
et al., 2010) can be represented as follows:
β =
2M
2M +1
(1.3)
and
M = log2
(
β
1−β
)
(1.4)
Assessing experimental quality. This step includes visual inspection of control
probes that enable one to assess the quality control of different sample preparation
steps such bisulphite conversion, hybridization, staining, among others. This step
can be conveniently visualized using the minfi package (Aryee et al., 2014).
Probe filtering. The filtering of probes is necessary to eliminate any possible
noisy signal. Probes with low quality signals should be removed by using the
detection P-value threshold (P > 0.05) (Dedeurwaerder et al., 2013). Further, probes
residing in the single nucleotide polymorphism (SNP) loci, which may also result in
noisy signals and cross-reactive probes (Chen et al., 2013), showing spurious cross
hybridization (Wilhelm-Benartzi et al., 2013) also need to be removed. In addition,
probes localized at the X and Y chromosomes are removed if the researcher wants
to eliminate sex-associated methylation effect.
Normalization. This is one of the crucial steps in data processing, which in-
volves the removal of variation that is not related to biological properties, but rather
the technical variation (Dedeurwaerder et al., 2013). Normalization of methylation
data includes within-array normalization and between-array normalization. (See
Table 1.2.1)
Within-array normalization involves background correction as well as type I
and II probe scaling (Wilhelm-Benartzi et al., 2013; Dedeurwaerder et al., 2013).
The former involves the removal of any non-specific signal from the overall signal,
correcting any possible between array artifacts (Wilhelm-Benartzi et al., 2013)
which can be facilitated by the minfi package(Aryee et al., 2014). Further, Illumina
First Sample Normalization (IFSN) is a classical within-array normalization proce-
dure used for the HM450K array, which adjusts for this variability of color signals
(Yousefi et al., 2013) and can also be used in this regard.
The HM450K array utilizes two types of assays, Infinium I and Infinium II, for
methylation profiling. About 72% HM450K probes use the latter in cases where
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unmethylated and methylated signals are measured by a single bead (Bibikova
et al., 2011). On the other hand, the remaining probes are profiled using the
Infinium I assay, wherein unmethylated and methylated signals are measured by
different beads in the same color channel. However, the two types of probes used
the in the HM450K array may not have the same methylation distribution, causing
biased estimation of methylation measure (Dedeurwaerder et al., 2013). The most
commonly used methods to eliminate type I and II bias, which are discussed below.
Unlike gene expression microarrays, direct application of quantile normaliza-
tion is not suitable in this regard, since type I and II probes do not measure the
same CpG, thereby varying the distribution of β values between these probe types
(Dedeurwaerder et al., 2013). However, Subset-quantile Within Array Normal-
ization (SWAN) implemented in the minfi package (Aryee et al., 2014) matches
the Type I and Type II β distributions , by applying a within-array quantile nor-
malization separately for different subsets of probes (Maksimovic et al., 2012).
However, one of the pitfalls of the SWAN based approach is that it is not suitable
when a global methylation difference is expected, such as cancer/normal studies
(Dedeurwaerder et al., 2013) or between-tissue studies. Functional normalization,
can overcome this problem, which by default applies to the preprocessNoob, func-
tions as a first step for background subtraction and uses the first two principal
components of the control probes in order to determine the unwanted variation.
Another alternative normalization approach is beta-mixture quantile normalization
(BMIQ) (Teschendorff et al., 2012), which can be used if a variation is present in
the shape of methylation distribution. This method decomposes the density profiles
of Infinium I and Infinium II probes into two mixtures of three distributions based
on the three methylation states: unmethylated (close to 0), partially methylated
(close to 0.5), and fully methylated (close to 1). Furthermore, (BMIQ) employs
a quantile normalization to fit each distribution of the Infinium II profile to the
corresponding distribution of the Infinium I profile. Unlike (SWAN), (BMIQ) is
assumption free and does not depend on arbitrary choices concerning biological
characteristics in order to perform normalization (Dedeurwaerder et al., 2013).
Between array normalization is used to normalize the data between the arrays
and can be performed using shift and scaling using lumi R package (Du et al.,
2008). For more information on this procedure, refer to Wilhelm-Benartzi et al.
(2013); Dedeurwaerder et al. (2013).
In the publications referred to in this thesis, we utilized Illumina First Sample
Normalization (IFSN) which provided good quality data to reveal tissue-specific
methylation patterns in Publication I. However, for Publication II, we observed that
methylation differences in the type I and type II probes resulted in large bias and
variation. Therefore, BMIQ normalization resulted in the generation of the most
suitable data for further analysis. In Publication III, between array normalization,
in conjunction with a shift and scaling approach, was utilized since this method
fitted our data according to the clustering approach (Figure 13).
21
Method Normalization
type
Description R Packages
Illumina W and BA Background correction
and reference normal-
ization
minfi
PBC W and BA Type I and II probe bias
correction
ChAMP
QN W and BA The probe intensities
for all the samples are
made identical
minfi
SQN W and BA Type I and II probe bias
correction
minfi
SWAN W Type I and II probe bias
correction
minfi
FN BA Removes unwanted
technical variation
using control probes
minfi
NOOB W Background correction
and adjustment of dye
bias
Methylumi
BMIQ W Type I and II probe bias
correction
waterRmelon,
ChAMP
DASEN BA Background correction
and quantile normal-
ization separately per-
formed for Type I and
II probes
waterRmelon
Table 2. Summary of different normalization procedures available for the HM450K
array. PBC: Peak-based correction; QN: Quantile normalization; SQN: Subset-quantile
normalization; SWAN: Subset-quantile witharray-normalization; FN: Functional normal-
ization; NOOB: Normal-exponential using out-of-band probes; BMIQ: Beta-mixture
quantile normalization; DASEN: Data-driven separate normalization; W: Within array;
BA: Between array normalization.
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1.2.2. Batch effect correction
The batch effect corresponds to non-biological variation that may arise among
the batches of samples that are not processed on the same day, or when differ-
ent scanners are used in this process, when it is performed by different persons
(Dedeurwaerder et al., 2013), or when it is performed at different labs. Moreover,
the position of the array on the slide from the same batch of samples may lead
to the generation of non-biological variations (Dedeurwaerder et al., 2013). A
comprehensive definition of the batch effect can be found in a review article Lazar
et al. (2012). Owing to the aforementioned reasons, it is important to correct these
confounding factors before proceeding to any further analysis.
Methods to correct the batch effect have been briefly described below:
Empirical Bayes method. The Empirical Bayes method implemented in Com-
Bat (Johnson et al., 2007), originally designed for gene expression microarrays
can be used for batch effect correction in HM450K data implemented using the
ChAMP package (Morris and Beck, 2015). ComBat uses parametric and/or non-
parametric Empirical Bayes frameworks for adjusting the batch effects within the
data. Furthermore,the input data for ComBat needs to be cleaned and normalized
prior to the batch effect removal. ComBat’s performance has been noted to be
robust towards outliers (Dedeurwaerder et al., 2013).
BEclear. BEclear is a batch effect correction method used for HM450K data,
which was developed over the recent past. To summarize, BEclear adjusts the por-
tions of the data identified to differ significantly from the other batches (Akulenko
et al., 2016). More details pertaining to BEclear is available in Akulenko et al.
(2016).
To sum up, batch effect correction enables minimization of any possible un-
wanted non-biological variation. Further, it provides an opportunity to combine
samples from two or more studies that lie with in the same phenotype of interest,
thereby increasing statistical power and yielding robust results. In this thesis, we
utilized the Empirical Bayes method (Johnson et al., 2007) to adjust the batch effect
between Oxford and Tartu samples in order to analyze menstrual cycle specific
methylation patterns in Publication II.
1.2.3. Correlation analysis
Correlation analysis is a statistical approach adopted to explore the relation between
two variables. The most widely used methods for performing the said analysis
have been described below:
Pearson’s correlation coefficient (PCC). Let us assume that we want to deter-
mine the linear relationship between two variables x and y. The Pearson-product
moment correlation coefficient (r) can be expressed as
r =
∑ni=1(xi− x)(yi− y)√
∑ni=1(xi− x)2(yi− y)2
(1.5)
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In this equation, n denotes the sample size x and y represent the sample means of x
and y respectively.
Spearman’s rank correlation. Since Pearson’s correlation assesses the linear
relationship between the samples, one can alternatively use Spearman’s correla-
tion that assesses monotonic relationships (whether linear or not). Spearman’s
correlation can also be defined as the PCC between the ranked variables, and it
can be computed using the following formula:
ρ = 1− 6∑d
2
i
n(n2−1) (1.6)
In this equation, ρ denotes the PCC applied to the ranked variables. di signifies the
distances between the ranked variable and n represents the number of observations.
The correlation measure is always expressed between -1 and +1. A value close
to 0 can be interpreted to signify no relation between the tested variables, while a
value close to +1 and -1 denotes high positive correlation and negative correlation,
respectively.
In this thesis, we applied PCC to compute the correlation across methylation
levels in tissues and also to integrate gene expression with methylation profiles
in Publication I. In Publication III, we computed Spearman’s rank correlation in
order to calculate the correlation between gene expression and methylation levels
in pre-receptive and receptive endometrium to obtain insights on the effects of
methylation at transcriptional levels. Finally, both PCC and Spearman’s rank
correlation were implemented to generate heat map visualization for the web tool
MethSurv described in Publication IV.
1.2.4. Principal component analysis
Principal component analysis (PCA), a method to reduce the dimensionality of
data (Pearson, 1901; Yeung and Ruzzo, 2001) can be applied to genome-wide
methylation data for meaningful interpretation and exploration. PCA reduces
high dimensionality by identifying directions, called principal components, along
which the variation in the data is maximal. These principal components are
linear combinations of the original variables present in the high dimensional data
(Ringnér, 2008). An illustrative example of a three dimensional PCA plot from
the subset of tissue methylation data obtained from Publication I, highlighting the
separation of brain and adipose tissues has been provided in Figure 6. In this figure,
the first principal component describes the direction along which the samples
show the greatest variation. Moreover, every component is uncorrelated to the
previous ones, which maximizes the variance of the samples when projected onto
the component. In PCA, the direction depicting the variances are eigenvector shown
by PC1 and PC2 in Figure 6 and the corresponding the eigen value explains the
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variance of the data in the respective direction. Additionally, in this figure, PC1 has
the highest eigenvalue and therefore, the first principal component. On the contrary,
PC2 contain the second highest eigenvalue is the second principal component and
so on (Peterson, 2015). A detailed description of PCA in genome-wide data is
provided in Ringnér (2008).
In this thesis, we employed PCA in Publication II to visualize any possible
distinction between endometriosis patients and healthy controls. In Publication IV,
PCA was implemented in the web tool MethSurv to identify patterns in the gene
methylation with respect to patient’s characters such as age, gender, among others.
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Figure 6. PCA plot of the tissue methylation data obtained from Publication I, show-
ing the separation between adipose and brain tissues. PC1 denotes 64% variability,
PC2 denotes 10.3% variability.
1.2.5. Cluster analysis
Cluster analysis or data clustering involves grouping a set of data points that are
similar to each other based on certain criteria. Several algorithms are available
to perform data clustering. Hierarchical clustering, a prominent approach in this
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regard, which is also known as connectivity-based clustering wherein the clusters
are built on the basis of hierarchy, will be briefly discussed in this section. In
the said clustering, a binary tree is constructed by successive merging of similar
samples or probes based on similarity measure (Eisen et al., 1998). Hierarchical
clustering includes agglomerative and divisive hierarchical clustering (Wang and
Petronis, 2008) which have been briefly discussed below.
Agglomerative hierarchical clustering. It is based on the bottom-up approach
wherein the underlying method tends to find and merge two clusters based on
the shortest distance. Moreover, between-cluster distance is calculated based on
the centroid of the merged clusters (Wang and Petronis, 2008). For instance, one
member from a particular cluster is paired with another member of the other cluster
after which the pairwise-distance is thus calculated. This approach can also be
termed as complete linkage clustering (Wang and Petronis, 2008).
Divisive hierarchical clustering. The underlying principle of this clustering is
exactly the opposite to that of agglomerative hierarchical clustering. To elaborate,
this approach begins with a single cluster and the point comprising the largest
pair-wise distance to the other point is chosen. Subsequently, it is split from the
initial cluster resulting in the formation of a new cluster.
The results of hierarchical clustering can be conveniently visualized using a
dendrogram, which provides a visual overview of relationship between the samples.
A detailed description of hierarchical clustering can found in (Wang and Petronis,
2008).
In this thesis, hierarchical clustering analysis was a significant method for data
visualization. In Publication I, the hierarchical clustering approach revealed tissue-
specific methylation patterns, while in Publication II, it provided a visual overview
of the strong batch effect between Oxford and Tartu methylome profiles. Further-
more, in the case of the latter, it also demonstrated menstrual cycle methylation
patterns following batch effect correction. Lastly, in Publication IV, we employed
the hierarchical clustering approach to visualize the methylation patterns of CpGs
within the vicinity of a gene, in order to capture methylation differences across
different genomic regions.
1.2.6. Differential methylation analysis
The said analysis is performed to identify the genomic regions associated with
differential methylation status across different biological samples. Differential
methylation can be conducted either at single CpG level, called differentially
methylated positions (DMP) or at the region level called differentially methylated
regions (DMR). DMP analysis can be performed using a simple t-test, or Bayes
moderated t-test (Smyth, 2005) which can be implemented by the ChAMP package
(Morris and Beck, 2015). It must be noted that the t-test is based on the assumption
that the samples are normally distributed. However, the condition of normality
may not always hold true for certain kind of methylation datasets (Wang and
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Petronis, 2008). Therefore if one wants to perform statistical tests based on no
prior assumptions regarding the methylation data distribution, non-parametric
tests such as Wilcoxon signed-rank test or Wilcoxon rank-sum test can be used
(Wang and Petronis, 2008). The former can be performed if the methylation data
comprises matched data (for instance, methylation levels are measured before and
after fasting for the same set of individuals) whereas the latter can be used for
unmatched methylation data.
Since DMP analysis focuses on individual CpG sites, ignoring any possible
correlation with nearby CpG sites, it may produce biased and redundant results.
In particular, the HM450K array provides spatially distributed DNA methylation
structure that is often expected to have similar methylation profiles (Kolde et al.,
2016). On the other hand, the DMR methods are based on the assumption that
nearby probes on a given window size tend to demonstrate the same behavior
(uniformly hyper or hypomethylated) (Dedeurwaerder et al., 2013), thus yielding
statistically more sensitive and powerful results (Kolde et al., 2016). The region-
based analysis pipeline presented in the IMA package (Wang et al., 2012) treats
each predefined genomic regions such as CGI, as a separate unit and performs
differential methylation analysis accounting for the statistical significance (P <
0.05). Such analysis may often result in larger regions covering the same set of
differentially methylated sites (Kolde et al., 2016). Alternatively, one can use
the bump hunting algorithm (Jaffe et al., 2012), which performs differentially
methylation analysis on spatially smoothed data and subsequently aggregates the
individual sites into a region. Further, the results of the said algorithm depend
on the parameters supplied by the user (Jaffe et al., 2012; Kolde et al., 2016).
These parameters may include parameters such as effect size cut-off and smoothing
window size (Kolde et al., 2016).
Another powerful DMR based approach is seqlm (Kolde et al., 2016), which
provides flexible parameters to determine DMRs. The main steps of DMR identifi-
cation in seqlm (Kolde et al., 2016) can be briefly described as follows:
1. Genomic segments are established according to the user specified threshold
(e.g. 500 bp)
2. The segments obtained from the aforementioned step are divided into regions
based on fitting a linear model into the sliding window. The minimum de-
scription length (MDL) principle (For more details, See Kolde et al. (2016))
is applied to the fitted model accounting for longer regions as well as the
goodness of the model fit (Kolde et al., 2016). This is because methylation is
known to be regulated in longer regions (Lienert et al., 2011) and may have
better biological implications.
3. Once an optimal genomic regions are derived using the aforementioned steps,
a linear mixed effect model as depicted below is fitted to derive statistically
significant DMRs.
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yi j = µ j +βxi +bi + εi j (1.7)
In this equation y signifies the response variable denoting the methylation value
of the sample i and site j. While µ denotes the baseline methylation value, β
represents the average effect size within the region and x signifies the phenotype
of interest (e.g. age). Moreover, bi denotes the random effect which accounts for
within-sample correlation and ε represents the standard error.
In this thesis, seqlm was initially developed in Publication I to establish tissue
specific DMRs but was subsequently established into a separate method that was
published in Kolde et al. (2016). Further, seqlm was used to evaluate the difference
in methylation between both endometriosis patients and healthy controls in addition
to the difference among the menstrual cycle groups in Publication II. On the other
hand, in Publication III, seqlm, along with other methods was used to determine
the true set of differently methylated CpG sites between the pre-receptive and
receptive states of the endometrial tissue.
1.2.7. Gene enrichment analysis
Once differential methylation analysis has been performed, it is important to
statistically relate the results (usually a genomic loci or CpG sites, that are further
related to genes) to gene functional categorie;, this process is termed as gene
enrichment analysis. There are several ways to relate the gene list in order to make
meaningful biological interpretation which have been discussed below.
Enrichment using Gene Ontology (GO) terms. The gene list can be related to
Gene Ontology (GO) terms which can be facilitated by the GO (Ashburner et al.,
2000),i.e., a large collection of genes described by a controlled vocabulary (Peter-
son, 2015). GO comprises of the vocabularies (also termed as ontologies) that are
hierarchically structured with the molecular function (MF), biological process (BP)
and cellular component (CC). GO terms constitute the main elementary unit of GO
wherein the relationship between each of these terms is represented by a directed
acyclic graph (DAG). In other words, GO terms constitute a hierarchy in which
every gene could be annotated with one or more terms in each ontology (Eden et al.,
2009) and may further associated with the parent term. For instance, cell death
(GO:0008219) is a child term of cellular process (GO:0009987) while the term cel-
lular process is linked to other cellular processes such as regulation of euchromatin
binding (GO:1904793), regulation of core promoter binding (GO:1904796) and so
on.
Enrichment with biological Pathway. Apart from GO, one may wanted to relate
the gene list derived from differential methylation analysis to biological pathways
(e.g, steroid hormone biosynthesis) using pathway knowledge bases such as KEGG
(Kanehisa and Goto, 2000), BioCarta (Team, 2001) and Reactome (Joshi-Tope
et al., 2005).
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Linking with other resources. In addition to GO and pathway analysis, it is possi-
ble to evaluate and associate the enrichment of the gene list procured from differen-
tial methylation analysis with protein complexes facilitated by the knowledge-base,
CORUM (Ruepp et al., 2007), transcription factor enrichment using TRANSFAC
(Matys et al., 2003) and human diseases using The Human Phenotype Ontology
(Robinson et al., 2008).
A web tool g:Profiler, (Reimand et al., 2007, 2016) can be conveniently used
for gene set enrichment analysis. The tool g:Profiler utilizes hypergeometric tests
to determine whether the inputted gene list overlaps with functional categories
(such as GO term, pathways, transcription factor enrichment and so on) followed
by multiple testing correction when several categories are tested (Reimand et al.,
2007). The options available for multiple testing correction in g:Profiler includes
Bonferroni, Benjamin and Hochberg (BH) and g:SCS that is a custom threshold
(Reimand et al., 2007). Apart from g:Profiler, there are many other tools available
for the research community to facilitate gene enrichment analysis - such as, GOrilla
(Eden et al., 2009), DAVID (Huang et al., 2008), topgo (Alexa and Rahnenfuhrer,
2010) to name a few.
In some cases, gene enrichment analysis may result in the generation of several
hundred terms, which may be difficult to interpret. One possible approach to
tackle this issue is to visualize gene list enrichment analysis in the form of word
clouds, facilitated by GOsummaries (Kolde and Vilo, 2015) implemented in a
bioconductor package. GOsummaries implements custom methods to filter GO
enrichment results which depend on the size of the terms and the relationship
between each term (See Kolde and Vilo (2015) for more details). Further, the
font size in the resulting word cloud is directly proportional to the strength of the
enrichment. (Kolde and Vilo, 2015).
We utilized DAVID to perform gene enrichment analysis pertaining to tDMRs in
Publication I and g:profiler to understand the functional relevance of menstrual cy-
cle specific genes in Publication II. On the other hand in Publication III, we utilized
g:Profiler, GOsummaries to understand the functional relevance of differential
methylation between pre-receptive and receptive endometrium.
1.2.8. Survival prediction using methylation data
As mentioned in section 1.1.3, methylation patterns are a promising biomarker
candidate for patient survival prediction. To associate methylation levels with
patient survival, one possible approach is to perform Cox-proportional model
fitting for the patient i as shown below:
hi(t) = h0(t)exp(β iX i) (1.8)
In this equation X = (X1,X2) and X1 is the CpG methylation level while X2 rep-
resents clinical covariates such as age, BMI, stage, grade and so on. Moreover,
h0(t) is the baseline hazard, h0(.) is the arbitrary baseline hazard function, while
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β is a vector of regression coefficient (not be to confused with methylation β
values). Survival analysis can be performed accounting for both the univariable
and multivariable models. In univariable analysis, probe’s methylation status is
an explanatory variable and while survival time function is the response variable.
In multivariable analysis, in addition to the methylation status, clinical covariates
such as age, sex, stage among others can be included in the model. Additionally
differential survival can be assessed by dichotomizing the patient’s methylation
level into higher and lower methylation. The cut-off point for such dichotomization
can be computed based on the mean or data quantiles. However, to evaluate of
all possible cut-off points in the continuous methylation β values, the method
concerning Maximally Selected Rank Statistics (maxstat) (Hothorn and Lausen,
2003) can be used. For more details on maxstat, See Hothorn and Lausen (2003).
In principle, maxstat assesses all of the data points obtained from the continuous
methylation data and establishes a cut off point where the standardized statistics
take their maximum significance regarding the separation of patient groups. The
resulting Cox model fit provides, hazard ratio (HR) with 95% CI. On the other
hand, the likelihood-ratio (LR) test and Wald test allows to assess the goodness of
Cox model fit. The assumption of Cox proportionality is tested using proportional
hazards assumption test.
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2. TISSUE SPECIFIC METHYLATION PATTERNS
(PUBLICATION I)
This chapter focuses on the understanding methylation patterns that are specific
to different somatic tissues. The data was provided by our project collaborators
from Estonian Genome Centre, University of Tartu. We developed and provided
the bioinformatics workflow to support the data analytics and interpretation of this
project. The methylation data used in this research were unique at that time of the
study, concerning the tissue samples and the choice of the array. For instance, it in-
cluded methylation data obtained from the same set of individuals covering somatic
tissues from numerous tissue systems of the body such as nervous system (medulla
oblongata and ischiatic nerve), circulatory system (aortas and arteries), digestive
system (gastric mucosa), skeletal system (adipose tissue, bone and joint cartilage),
excretory system (bladder and gallbladder), and so on (See Figure 7). The primary
goal of this study was to understand whether there were tissue specific-methylation
patterns (tissue-specific biomarkers). A few of the fundamental questions while
initiating the project were concerned with data processing and analysis such as
how the tissues are related to each other regard to the methylation patterns are how
tissue-specific methylation patterns are related to gene expression. During this
study, data processing which includes normalization, data cleaning, and filtering
before downstream analysis played a very crucial role in identifying tissue-specific
biomarkers.
Some of the key methodologies, results and the contribution to Publication I
are described in the following sections.
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Brain
Aorta
Arteries
Joint cartilage
Bone
Adipose
Bone marrow
Tonsils
Bladder
Gastric mucosa
Lymph node
Figure 7. This figure depicts the list of tissues studied for methylation profiling in
the current chapter. Figure modified from Wikimedia (2012).
2.1. Data processing
The methylation data were pre-processed using the standard pipeline suggested
by the minfi package (Aryee et al., 2014) and the probes residing on the X and Y
chromosomes as well as SNP regions were filtered out. (See section 1.2.1). The
probability density plot of the processed methylation data showed that most of the
CpGs were either fully unmethylated or fully methylated in the somatic tissues
shown in Figure 8.
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Figure 8. Methylation distribution of the tissues. Global methylation distributions of
tissues (70 samples) along with the positive (fully methylated) and negative (fully unmethy-
lated) controls are represented as the density plot. The X axis corresponds to methylation
beta values ranging from 0 to 1, while the Y axis represents the frequency. From the global
distribution plot, It can be seen that most of the CpGs are either unmethylated or fully
methylated in the somatic tissues.
2.2. Clustering analysis
Hierarchical clustering analysis (See Section 1.2.5) along with complete linkage
was performed on the processed methylation data in order to obtain a general
relatedness profile between the tissues. Moreover, the hierarchical clustering of
tissue methylation data showed that similar tissues were clustered together, instead
of individuals being clustered together (eg. bone marrow red and yellow. See
Figure 9), suggesting that tissues with similar functions exhibit similar methylation
profiles. Therefore, methylation patterns are sufficient for the classification of
tissues.
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Figure 9. Hierarchical clustering of 17 tissues based on methylation levels. Hierarchi-
cal clustering dendrogram was generated using complete linkage. Similar tissues (e.g.,
arteries, aortas and brain tissues) are clustered together based on their methylation patterns.
It is also evident that tissues exhibit higher level of similarity compared to individuals. The
tissue number followed by the special character (*, ’) denotes a technical or biological
replica.
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2.3. Comparison of methylation distribution in different
genomic regions
We compared the methylation distribution of tissues in different gene sub-regions
and CGI using a novel visualization approach represented by the binned box and
whisker plot (binbwplot). The plot provides a clear understanding of the low and
high methylation patterns, which can be compared within and between different
gene sub-regions. The bin-bw plot showed that tissues exhibited high methylation
levels in places where transcription is not usually initiated (gene body and 3’UTR)
and low methylation levels in the vicinity of promoter regions (TSS200, TSS1550
and 3’UTR) and CGI regions (See Figure 4 from the Publication I). These findings
are in line with the classical gene model in which lower methylation in the promoter
and CGI regions may favor the binding of transcriptional proteins to the gene.
2.4. Tissue specific differentially methylated regions (tDMRs)
Differential methylation analysis was performed to identify genomic regions with
distinct methylation profiles across the studied tissues. First, we evaluated some
of the standard differential analysis methods including Bayes moderated t-test
and Wilcoxon rank sum test (data not shown). Due to the disadvantages of the
aforementioned methods, our co-authors developed a novel method for differential
methylation analysis (See Section 1.2.6). The approach of this method aimed to
identify longer genomic regions that are differentially methylated in one tissue
compared to other tissues. Subsequently this method was published as Seqlm
(Kolde et al., 2016) for exploring differentially methylated regions. DMR analysis
revealed that every tissue has its distinctive methylation patterns (See Figure
10 for an illustrative visualization of a tDMR region differentiating bladder vs.
all other tissues). However, the number of tDMRs varies significantly among
different tissues (See Table 1 of Publication I). The highest number of tDMRs was
found in tonsils followed by medulla oblongata, whereas the lowest number of
tDMRs was found in the lymph nodes. In addition to tDMRs present in promoter
regions we reported higher preference of tDMRs in gene body (Fisher’s exact
test, P < 2.2×10−16), which are further supported by recent studies by Yang et al.
(2014); Teissandier and Bourc’his (2017). However, the biological functions of
gene body’s tissue methylation need to be elucidated experimentally.
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Figure 10. Visualization of the bladder specific DMR region visualized using seqlm
(Kolde et al., 2016). This illustrative figure show the bladder specific DMR region (red) in
comparison with the other tissues (blue). The horizontal axis corresponds to the CpG site,
while the vertical axis corresponds to the methylation beta values, ranging from 0 to 1.
2.5. Integrating tissue methylation profiles with gene
expression data
We performed integrated analysis of gene expression levels and tissue methylation
profiles in order to understand the functional role of methylation in gene expression
regulation. Since we do not have gene expression measures from the original
tissues used in this study, we searched the expression of matching tissues from the
public gene expression repository, gene expression omnibus (GEO) (Edgar et al.,
2002) and array express (Brazma et al., 2003).
The association between methylation and gene expression levels was performed
using PCC (See Section 1.2.3 using two different approaches
• By correlating global tissue methylation levels with gene expression profiles
and
• By correlating tDMRs with gene expression profiles
Thus, the aforementioned approaches clearly distinguishes the functional role
of tDMRs compared to global methylation.
The methylation and gene expression correlation analysis showed more number
of negative correlations than positive correlations (See Table 3 and Table 4 from
Publication I for more details) (Fisher’s exact test, P < 2.2×10−16).
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2.6. Summary and impact
In this article, we explored the significance of tissue-specific methylation patterns
that are crucial for the classification of tissues. The methylation levels of selected
tDMRs (See Publication I for more details) in this study were validated by our
collaborators using traditional Sanger sequencing. This validation gave us further
confidence on our bioinformatics workflow. Hence our workflow can be adapted
for similar studies. Additionally, the data used in this study have also been used
for determining imprinting genes by Pervjakova et al. (2016). Further, the method
of DMR analysis applied here was developed into an independent tool and pub-
lished by Kolde et al. (2016). Moreover, our article highlighting tissue-specific
methylation patterns (Lokk et al., 2014) is an unique study and was one of the top
ten highly accessed of the journal Genome Biology journal for that particular year.
Further, Publication I has been cited by over 170 publications till date (retrieved
from google scholar, 11/04/2019).
2.7. Contribution
In this project, I worked on processing the raw methylation data, evaluating differ-
ential methylation methods, and identifying gene expression data from publicly
available databases. I also downloaded, normalized, performed further integrated
analysis of methylation with gene expression data, and worked on data visualization.
In addition, I drafted the manuscript related to my contribution.
37
3. MINING DISEASE SPECIFIC METHYLATION
PATTERNS IN ENDOMETRIUM (PUBLICATION II)
This chapter aims to find biomarkers differentiating endometriosis patients from
healthy individuals, based on methylation patterns. The methylation data used in
this project were generated by the project collaborators from Tartu and Oxford.
In the recent years, several research works conducted transcriptomics studies to
understand transcriptional changes in endometriosis disease progression. How-
ever, altered methylation patterns have been proposed to be a mechanism that
is possibly responsible for the initiation of endometriosis, apart from classical
transcriptomics. Moreover, considering the fact that endometrium undergoes cyclic
changes (Houshdaran et al., 2014), menstrual phase-specific changes must be
considered while analyzing endometrial methylome in relation to the disease sta-
tus. Therefore, we aimed to examine menstrual cycle-specific DNA methylation
patterns in the endometrium of endometriosis patients and controls. This study
included endometrial methylation profiles obtained from 31 endometriosis patients
and 24 controls. It also contained methylation data throughout the menstrual cycle
phase (28 days) described as follows: menstrual (M, n = 5), proliferative (P, n =
5), early secretory (ES, n = 8), mid secretory (MS, n = 26), and late secretory (LS,
n = 11). In this project, we provided complete bioinformatics analytical support
to achieve data processing, visualization, and differential methylation analysis
between endometriosis patients and controls as well as between different menstrual
cycle phases. The key challenges included data processing such as normalization,
in addition to batch effect correction and data visualization.
3.1. Data processing
This process begins with the normalization of the methylation data. We normal-
ized the said data using Beta-Mixture Quantile (BMIQ) normalization procedure
(Teschendorff et al., 2012) (See Section 1.2.1). Furthermore, the samples used in
this project were prepared in two different laboratories, i.e., in Tartu and Oxford.
We observed a strong batch effect in the samples, which was evident from the
sample clustering analysis, wherein samples were clustered according to the lab
instead of the disease status or menstrual cycle phase, as shown in Figure 12.
The batch effect was corrected using ComBat (Johnson et al., 2007) (See Section
1.2.2).
3.2. PCA and clustering
PCA and clustering was performed to visualize the methylation data patterns with
respect to menstrual cycle phases and/or disease status. In this study, the PCA
(See Section 1.2.4) showed no distinction between the endometriosis patients and
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controls (Figure 11). Further, the hierarchical clustering analysis (See Section
1.2.5) clearly demonstrated that the methylation profiles were clustered together
by the menstrual cycle phases rather than the disease status (See Figure 2 from
Publication II).
Figure 11. PCA plot of all endometrial and control samples after normalization.
Endometriosis samples are denoted by red circles, while healthy controls are denoted by
blue triangles. There is no distinction between the endometriosis patients and controls
according to the PCA.
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Figure 12. Hierarchical clustering analysis of all endometrial and control samples
before batch effect correction. Samples in blue and black corresponds to Oxford and
Tartu samples, respectively. The cluster dendrogram demonstrates samples were clustered
according to collection center and not by disease status
3.3. Differential methylation analysis
Differential methylation analysis was performed between endometriosis patients
and controls as well as between the menstrual cycle phases using seqlm method
(Kolde et al., 2016) (See Section 1.2.6). Moreover, DMR analysis between en-
dometriosis patients and controls revealed only 28 differentially DMRs. However,
none of the DMRs remained significant after adjusting for co-variates such as age,
nationality and body mass index (BMI). On the other hand, DMR analysis between
the menstrual cycle phases, particularly adjacent menstrual cycle phases (M vs.
P, MS vs. LS and LS vs. P) revealed large scale substantial methylation changes
between the menstrual cycle groups, when either or both M and LS are included
in the analysis (Saare et al., 2016) (See Table 2 from Publication II). This could
be owing to the fact that the endometrial tissue undergoes major morphological
changes including thickening during the LS phase and desquamation during the M
phase, which are reflected in their methylation patterns as well. The entire DMR
analysis presented here was corrected for false discovery rate (FDR<0.05).
3.4. Summary and impact
In this study, we analyzed the methylation changes taking place in the endometrium
of endometriosis patients and healthy controls by considering menstrual cycle
specific methylation changes. The results of this study suggests that overall en-
dometrial DNA methylation patterns are highly similar between patients with
endometriosis and healthy women. However, methylome changes may be primar-
ily influenced by the menstrual cycle phases. Although DNA based diagnostic
biomarkers are largely suggested for clinical set ups, especially for cancer and
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mental disorders (Kim et al., 2018), our results suggest that methylation-based
biomarkers may not be beneficial for the classification of endometriosis patients.
3.5. Contribution
In this project, I was responsible for the entire data analytics process, including data
pre-processing, batch effect identification and correction, clustering analysis, PCA,
evaluation of DMR methods and data visualization. I also drafted the manuscript
related to my contribution.
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4. METHYLOME ANALYSIS DURING THE
TRANSITION FROM PRE-RECEPTIVE TO
RECEPTIVE ENDOMETRIUM (PUBLICATION III)
In the previous chapter, we focused on identifying disease-specific endometrial
biomarkers. In the current chapter, we focus on the methylation patterns of healthy
and fertile endometrial tissue, emphasizing methylation changes that take place
during the transition from the pre-receptive to the receptive endometrium. It is
important to study the methylation changes during this transition since successful
implantation of an embryo requires synchronization between a healthy embryo
and a functionally competent endometrium (Mahajan, 2015). This phenomenon
is termed as window of implantation (WOI) or endometrial receptivity. The WOI
corresponds to the mid secretory phase (19–24 days) of a regular menstrual cycle.
Therefore, our study included endometrial methylation profiles from the early
secretory and to the mid secretory phase.
Numerous studies suggested a multitude of transcriptional changes that take
place during the transition from the pre-receptive to the receptive endometrium
(Carson et al., 2002; Díaz-Gimeno et al., 2014; Hu et al., 2014). Epigenetic modu-
lators, mainly DNA methylation, may play an essential role in the transcriptional
changes that take place during the WOI. For this reason in Publication III, we
investigated the methylation changes taking place during the said transition. We
also evaluated the methylation effect on gene expression changes by correlating
DNA methylation profiles with the gene expression data profiled using RNA se-
quencing. This study comprises endometrial methylome profiles of 17 healthy and
fertile women corresponding to the early secretary and mid secretory phase of the
menstrual cycle generated by our project partners from the Competence Centre
on Health Technologies, Tartu, Estonia. Our study utilizes an endometrial sample
from the same set of individuals, thus eliminating any inter-individual variation.
For gene expression-methylation correlation analysis, 14 biopsies of seven women
profiled using RNA sequencing were utilized.
4.1. Data processing
Preprocessing and normalization of the methylation data were conducted using the
bioconductor RnBeads package (Assenov et al., 2014).
4.2. Analysis of global methylation profiles of the
pre-receptive and receptive endometrium
First, we visualized global methylation patterns in the pre-receptive and receptive
endometrium using a probability density plot. The said plot (See Figure 1 of
Publication II) clearly showed that the methylation profiles between the two time
42
points were nearly similar. Further, the hierarchical clustering analysis (See Section
1.2.5) demonstrated that the methylation patterns were mostly clustered according
to the individuals (See Figure 13) .
4.3. Differential methylation analysis
As global methylation profiling showed that there may not be large-scale differences
between the pre-receptive and receptive endometrium, we expected to observe only
small-scale methylation differences between them. To explore these small-scale
methylation changes, we utilized site-level analysis methods such as RnBeads and
Wilcoxon signed rank-test to compute differential methylation. The former utilizes
a moderated t-test to compute differential methylation (DM). Moreover, the latter
was also used in the site-level analysis since the global methylation distribution
deviated slightly from the normal distribution (data not shown) (See Section 1.2.6).
In addition, we used the region-level analysis method seqlm (Kolde et al., 2016)
and extracted individual CpG sites from the DMRs for computing DM. Thus we
employed a combination of RnBeads and Wilcoxon signed rank-test and seqlm
for differential methylation and selected the intersection of the same to derive the
DM CpG sites to reduce any potential false positives and select the differential
methylation analysis results with greater confidence (See Figure 14).
The clustering analysis of DM sites clearly showed two main branches that
divided the methylation samples according to the pre-receptive and receptive
phase except for one sample that clustered together with receptive phase samples.
Additionally, three samples from the receptive phase were also clustered in the first
branch (See Figure 13).
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Figure 13. Hierarchical clustering analysis of the processed (A) methylation data
and differentially methylated data (B) from the pre-receptive and receptive en-
dometrium. ES – Early-secretory (pre-receptive LH+2) samples; MS – Mid-secretory
(receptive LH+8) samples.
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Figure 14. Venn diagram highlighting the overlap between the three meth-
ods (Wilcoxon, Rnbeads and seqlm) used for identifying differentially methylated
CpG sites between the pre-receptive (LH+2) and receptive phases (LH+8) of en-
dometrium.
4.4. Gene enrichment analysis
GO enrichment analysis was performed by g:Profiler (Reimand et al., 2007, 2016)
for the DM CpGs. Additionally, GOsummaries (Kolde and Vilo, 2015) was used
for summarized word cloud visualization (See Figure 5 from Publication III) based
on the results of g:Profiler. In site-level analyses, we found that CpGs mapped
with decreased methylation were primarily associated with immune response
regulation and cell activation and adhesion. On the other hand, in site-level analyses
with increased methylation, extracellular matrix organization, cellular signaling,
regulation, and development were prominent. The same trend was reflected in the
DMR analysis results as well (See Figure 5 from Publication III). In the case of GO
analysis with genes correlating with the gene expression, positively correlated genes
are related to extracellular matrix organization and immune response. Conversely,
we did not see any enrichment for negative correlations (Kukushkina et al., 2017).
4.5. Summary and impact
In Publication III, we analyzed the methylation changes taking place in pre-
receptive (LH+2) and receptive (LH+8) endometrium of fertile women within
the same menstrual cycle. Overall, our study’s results suggest methylation pro-
files have quite similar pre-receptive and receptive endometrium on a global scale.
However, small scale changes were detected using DM analysis.
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4.6. Contribution
In this publication, I contributed towards data processing, visualization and clus-
tering analysis. Moreover, I performed differential methylation using seqlm and
performed gene ontology analysis. I also drafted this manuscript related to my
contribution.
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5. MULTIVARIABLE SURVIVAL ANALYSIS ON
LARGE COLLECTIONS OF DNA METHYLATION
DATA (PUBLICATION IV)
In the previous chapters (Publications I–III), we provided the analytical pipeline
for evaluating DNA methylation biomarkers in healthy as well as diseased samples,
primarily using the methylation data derived from the project collaborators. It
is also possible to determine methylation biomarkers by using publicly available
methylation data. Moreover, cancer-based biomarkers are assessed by various
research groups, since aberrant methylation patterns serve as a hallmark for sev-
eral cancer types and remain an attractive biomarker candidate for cancer-risk
prediction, therapy management, and early diagnosis (Laird, 2003). In this project,
we used methylation and clinical data obtained from “The Cancer Genome At-
las” (TCGA) database to evaluate methylation-based prognostic biomarkers to
determine the survival time of cancer patients. The current chapter is based on
Publication IV, which addresses the second aim of this thesis, i.e., to develop a
web tool for correlating methylation levels with cancer survival time. Using the
developed web tool MethSurv, users can evaluate the prognostic potential of cancer
biomarker candidates across 25 different cancer types.
5.1. Survival analysis methods and visualization
After methylation data as well as clinical data was acquired from TCGA database,
we then matched the downloaded methylation data with the available clinical data
including survival status, patient characteristics (age, sex, height, weight, race, etc.)
and clinicopathologic features such as the stage and grade of the cancer, and so on.
(See Supplementary Table 1 from Publication IV for more details).
To perform survival analysis, we fitted Cox proportional hazards models (Cox,
1972) using the R survival package (Therneau, 2014). The patient’s methylation
levels were stratified according to mean, median, and lower or upper percentiles.
Moreover, the outcome oriented method was implemented using Maximally Se-
lected Rank Statistics (maxstat) (Hothorn and Lausen, 2002). The best cut-off is
derived according to the highest hazard ratio. MethSurv facilitates both univariable
(using only methylation levels in the prediction model) and multivariable survival
analyses (accounting for patient characteristics and clinicopathologic features in
addition to methylation levels in the prediction models) (See section 1.2.8).
Apart from survival analysis, it is also possible to explore methylation pattern
across a given gene in the form of a heat map using seamless integration with
ClustVis (Metsalu and Vilo, 2015). The entire pipeline adapted for the construction
of MethSurv has been shown in Figure 15.
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Figure 15. The pipeline adapted for the construction of Methsurv. Methylation, sur-
vival and clinical data were acquired from TCGA. Customized R script was used to match
methylation data with relevant survival and clinical data. Cox-proportional hazard model
was utilized to perform univariable and multivariable survival analysis implemented by
shiny web-interface. MethSurv contains five main components: (A) survival analysis for a
single CpG. (B) summarized tabular view for a query gene and genomic region. (C) clus-
tering analysis (PCA and heat map) for a query gene (D) top biomarkers for every cancer
and (E) data download options to download processed methylation data and pre-computed
survival analysis summary for every type of cancer.
5.2. Description of the user interface
Survival analysis for a single CpG query. Using the single CpG analysis tab
of Methsurv, users can conduct survival analysis for a single CpG for any of the
available genes. Using this feature, users can choose cancer type, gene, relation to
island, gene sub-region and a CpG site. In terms of statistical parameters, they can
choose which cut-off point to dichotomize patient’s methylation profiles (mean,
median, upper and lower quantiles, maxstat and best split). Upon selecting all
the required parameters, Methsurv generates the Kaplan-Meier plot (Figure 16)
with the statistical summary (HR with CI, proportional hazard P-value, Wald test
P-value, log-likelihood ratio test’s P-value for the model fit, proportional hazard
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test’s P-value and mean, median and range of methylation beta values). In addition,
the following have been displayed: a distribution plot highlighting the cut-off
points used for dichotomization and a violin plot depicting the distribution, median
and interquartile range of methylation profiles of the query CpG site in relation to
patient characteristics such as age, sex and stage (See Figure 2 from Publication
IV).
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Figure 16. Survival plot of cg00099393-PTPRN2 for endometrial carcinoma gener-
ated using Methsurv.
Users can view a tabular summary of the survival analysis’ results of all 25
cancers for a query gene using Methsurv’s “All cancers” tab. In addition, users can
also retrieve the survival analysis’ summary within a queried genomic region (e.g.
Chromosome 17 location: 41278000 to 41278000).
Identifying top survival biomarkers. Users can quickly browse through the most
significant biomarkers for each type of cancer using the "Top biomarkers" tab of
Methsurv.
Clustering analysis visualization for a query gene. Clustering analysis of a
given cancer and a query gene is facilitated in Methsurv using the "Gene visu-
alization" tab which allows users to visualize the clustering of individual CpGs
with in a query gene. This enables users to visually associate methylation levels
with patient characteristics (age, gender, and so on.) as well gene sub-regions.
In addition we also integrated Clustvis (Metsalu and Vilo, 2015) for advanced
clustering visualization in the form of a heat map and PCA (See Figure 17).
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Figure 17. A heat map depicting clustering analysis of EGFR using TCGA data
on lung adenocarcinoma. This heat map was generated using average linkage method
concenering correlation distance. Methylation levels (1 = fully methylated; 0 = fully
unmethylated) are shown as a continuous variable from ranging from a blue to a red color.
The rows correspond to the CpGs and the columns correspond to the patients.
Data download. Using the download option in Methsurv, users can download
processed methylation data matrix and clinical data for any of the available cancers.
It is also possible to download pre-computed survival analysis results in the form
of a table for any particular cancer type.
5.3. Example of MethSurv using the known biomarker
As an example of the evaluation of MethSurv’s usability, we compared MethSurv
results with the study results provided by Li et al. (2014). included 98 primary
breast tumor samples obtained from Shenzhen Maternal and Child Health Hospital
(independent of the TCGA samples). Li et al. (2014) showed that PTPRO promoter
hypermethylation is associated with poorer overall survival (HR = 2.7; 95% CI:
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1.1-6.2; P = 0.023). This effect can be observed in Methsurv (See Figure 4A from
Publication IV) using TCGA data for cg22374861-TSS200 annotated to PTPRO
(number of patients = 782; HR = 1.8; 95% CI: 1.2-2.7; P = 0.0054). More such
examples evaluating Methsurv results in conjunction with previously published
biomarkers are presented in Publication IV.
5.4. Summary and impact
In Publication IV, we analyzed large-scale methylation datasets for 25 different
cancer types from the TCGA. We observed that this large-scale data shows great
promise with respect to performing robust statistical analysis for survival predic-
tion. We further presented a web tool MethSurv to correlate overall cancer survival
with DNA methylation levels. Using MethSurv, users can perform univariable
and multivariable survival analyses with only methylation levels and methylation
levels as well as patient characteristics, respectively. In this way, we provide an
assessment of the way methylation, in combination with relevant clinical covari-
ates, may influence a cancer patient’s survival rate. We believe that MethSurv
can serve as a valuable resource for cancer biologists in generating hypotheses
pertaining to cancer biomarkers. To enable the usage of this web tool across a
wider scientific community, we made the tool interactive and easy to use, so that
even non-bioinformaticians can use it without any difficulty.
5.5. Contribution
I downloaded the data from the TCGA, processed and prepared the database for
the web interface, designed the query system, and drafted the entire manuscript.
Further, I researched the literature to prepare the datasets for the aforementioned
case study.
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6. DISCUSSION
Bioinformatics methods are required for analysis of large-scale biological data
and therefore remain central to accelerating biomarker discovery. The current
thesis identified methylation based biomarker candidates by using high quality
tissue samples from several experimental conditions. The thesis contributions were
twofold. Firstly, a comprehensive pipeline was introduced to identify methylation
biomarkers in different experiments. Secondly, a novel web-tool Methsurv was
developed.
The discussion part of the thesis starts with exploring the strengths and weak-
nesses of the experimental design followed by suggestions on future research and
final remarks.
6.1. Strengths and weaknesses of the studies
As mentioned in the preliminaries section (See Section 1.1.5), the entire thesis
utilizes methylation data profiled using the HM450K array. The HM450K array is a
powerful and cost-effective method of quantifying the DNA methylation status from
different cell or tissue types from the human genome. The HM450K array covers
several functionally known regulatory regions of genome (Bibikova et al., 2011).
Some of the major drawbacks of using this array includes unequal distribution
of the probes and coverage of fewer enhancer regions. Whole genome bisulfite
sequencing may successfully overcome the aforementioned probe selection bias
and comprehensive genomic coverage. However, higher costs and the need for
sophisticated computational resources compared to the HM450K array (Kurdyukov
and Bullock, 2016) must be borne in mind. Alternatively, one could choose a recent
and cost-effective technology Illumina MethylationEPIC BeadChip, which contains
an additional 350,000 CpGs, considered as potential enhancers, compared to the
HM450K array (McCartney et al., 2016).
The work presented in Publication I provided an opportunity to explore methy-
lation patterns of rare tissues or tissue subtypes. Moreover, the existence of tissue
specific methylation patterns highlighted in our study can be used for tissue identifi-
cation in a forensic context (Sijen, 2015). However, there are drawbacks which can
be improved for future studies. Firstly, the study was performed when the HM450K
array was newly introduced. Therefore, much of the technical advances made in
the recent years in terms of data analysis such as the discovery of cross-reactive
probes (Chen et al., 2013) and incorrectly reported methylation status due to the
presence of germ line or somatic mutations (Zhou et al., 2018) may therefore
confound region specific methylation patterns. Our hierarchical clustering and
DMR analysis results strongly support tissue-specificity. One of the interesting
future work would be to combine methylation data from our current study with
NIH Roadmap Epigenomics data (Kundaje et al., 2015) to describe extended tissue
specific methylation profiles. Some of the relevant tissues to combine include,
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oesophagus, thymus, liver and kidney.
The next part of the thesis focused on identifying methylation based biomarkers
in endometriosis disease prediction. Since endometrium tissue undergoes hormonal
changes throughout the menstrual cycle, our study included samples from the
entire menstrual cycle phase. Moreover, our study was the first to evaluate both
the menstrual cycle influences and endometriosis disease status at the same time
(Saare et al., 2016). However, some of the limiting factors of the experimental
study design include inter-individual variability, because of the diverse nature of
the samples from both Tartu and Oxford cohorts. Additionally a major drawback of
the study includes complexity of endometrium tissue, since endometrium consists
of different cell types such as epithelial, stromal and immune cells (Mortlock et al.,
2019). Though we demonstrated the elimination of cohort specific batch effect
(See Figure 12 and Figure 2 from Publication II), the results from Publication II
suggest methylation may not be a powerful indicator of biological changes taking
place in endometriosis according to, PCA (Figure 11), hierarchical clustering
(Figure 12) and differential methylation analysis (See Section 3.3). We next
identified methylation changes during the transition from pre-receptive to receptive
endometrium. Compared to Publication II, samples from Publication III included
endometrial tissues from the same set of individuals which eliminates any possible
inter-individual variability (Kukushkina et al., 2017). However, the problem of
endometrial tissue heterogeneity still exists. One of the suggestions to eliminate cell
type heterogeneity is to use single cell DNA methylation sequencing accounting
for epithelial and stromal cell types and subsequently use the same for reference
based cell-type composition adjustment (Teschendorff and Zheng, 2017; Titus
et al., 2017).
Next, in Publication IV, we utilized big data from TCGA, to identify methy-
lation based survival biomarkers for different cancer types. The Methsurv web
tool complements several existing web tools (Huang et al., 2014; Díez-Villanueva
et al., 2015; Koch et al., 2015; Xiong et al., 2016) for analyzing cancer methylation
patterns by including comprehensive visualization panels for survival outcome and
heat map visualization of CpG methylation patterns. Some of the drawbacks of our
tool are that Methsurv is applicable only for overall survival (Modhukur et al., 2017)
which limits survival analysis for specific cases such as treatment type, and drug
specific survival because of the limited number of samples. Although Methsurv is
a valuable intuitive tool for methylation based biomarkers, prospective studies are
needed to properly evaluate biomarkers for clinical practice. As a future work, it
would be interesting to compare survival predictions using the Cox-proportional
hazard model with the machine learning method, for example, random forest. As
an update, we will consider processing user’s own data for survival prediction.
Further, it will be intriguing for the bioinformaticians to develop novel methods
to classify tumor types based on TCGA methylation profiles (Angermueller et al.,
2016, 2017; Celli et al., 2018).
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6.2. Final remarks
The thesis has demonstrated the power of bioinformatics to identify methylation
based biomarkers. We also hope that the thesis provided a comprehensive set of
data analysis methods and web tool to understand how methylation patterns can
be translated into a diagnostic tool for clinical research. Moreover, the pipeline
presented in this thesis can be adapted for other high throughput data such as NGS
or other types of microarrays. We hope that we have convinced the readers about
the need for bioinformatics tools and methodologies to understand an exciting field
of science. Although we acknowledge the power of methylation based biomarkers
(Laird, 2003), we suggest the investigation of other epigenetic modifications in-
cluding histone modifications, chromatic modifications and microRNA expression
to understand the overall biological mechanism. Given enough computational
resources and funding, the next generation sequencing will be a promising tech-
nology to understanding epigenetic changes in the lab which potentially could be
used for diagnosis in the clinic.
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CONCLUSIONS
Methylation patterns are essential for a myriad of biological processes such as
growth and development; they are also associated with disease progression. This
thesis aimed to identify DNA methylation patterns as biomarker candidates in
normal and diseased human tissues using bioinformatics and statistical approaches.
To fulfill this aim, we worked on different biological experiments that are of high
value, since the tissue types and the experimental set-up was unique.
The first part of this thesis involves the application of bioinformatics methods to
identify methylation-based biomarker candidates. The primary bioinformatics anal-
ysis challenge is the appropriate selection of methods to decipher the methylation
patterns and eliminate any possible non-biological variation in order to identify
condition-specific biomarkers. To overcome these challenges and offer solutions
for the biological hypothesis, the following steps were followed:
• Performed hierarchical clustering analysis, which showed tissues can be
classified according to the methylation patterns provided in Publication I.
• Integrated analysis between gene expression patterns and tissue methylation
profiles using Pearson correlation coefficient in Publication I, which showed
an overall inverse correlation between gene expression and methylation.
• Performed batch effect correction of the said effect existing between the
experimental samples in endometriosis patients and controls and further
detected menstrual cycle methylation patterns of the endometrium in Publi-
cation II.
• Applied a careful selection of differential analysis methods which detected
small-scale methylation changes during the transition from pre-receptive to
the receptive endometrium in Publication III.
Overall, the methodological steps of the aforementioned pipeline can be cus-
tomized for other methylation datasets for the detection of methylation-based
biomarker candidates.
Subsequently the second part of this thesis focuses on the identification of
methylation-based marker candidates in order to detect survival time in cancer
patients. The work accomplished on these lines has contributed to the development
of a novel user-friendly web tool MethSurv, which is the first web tool for evaluating
methylation based survival biomarkers in Publication IV. MethSurv, tool enables
the scientific community easy to assess methylation based biomarkers by using
Cox-proportional hazard models. MethSurv uses methylation and clinical data
derived from TCGA, wherein the data processing, statistical calculations, and
visualizations can be a cumbersome task for non-bioinformaticians. In particular,
MethSurv, provides multiple options for the users including survival analysis based
on individual CpG, gene-specific survival, visualization of methylation patterns for
a queried gene in the form of a heat map and PCA. In this tool, top biomarkers for
each for cancer type are readily available. Moreover, all the recomputed results are
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available for the users to downloaded by users enabling further analysis queries.
Overall, the work presented in this thesis presented a comprehensive bioin-
formatics workflow used to identify methylation patterns as potential biomarker
candidates in various biological conditions. Further biological experiments con-
ducted in this regard will provide more evidence concerning the accessibility of
these biomarkers.
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SUMMARY
Haiguste ja koespetsiifiliste DNA metülatsioonil põhinevate
biomarkerite uurimine
DNA metülatsioon on epigeneetiline modifikatsioon, mis osaleb geeniekspressiooni
regulatsioonis. Seda modifikatsiooni seostatakse väga paljude oluliste bioloogilis-
te protsessidega nagu näiteks embrüonaalne areng, genoome vermimine ning X
kromosoomi inaktivatsioon. Teatud metülatsioonimustrid on seotud haigustega,
nagu diabeet, neuroloogilised häired või vähk. Seetõttu peetakse DNA metülat-
sioonimustreid ka headeks biomarkeri kandidaatideks, sobides iseloomustama
näiteks teatud haiguse kujunemist (või varajast staadiumi). Suuremahulised tehno-
loogiad, nagu mikrokiibid ja teise põlvkonna sekveneerimine (NGS), võimaldavad
luua ülegenoomse DNA metülatsiooniprofiili, mis on heaks vahendiks mõistmaks
geeniregulatsiooni. Üheks populaarseimaks DNA metülatsiooni mikrokiibiks on
Illumina HumanMethylation450K (HM450K) kiip (Illumina Inc., San Diego, CA,
USA), mis võimaldab kulutõhusalt hinnata metülatsiooni taset hästiiseloomustatud
genoomi regioonides.
Käesolev doktoritöö käsitlebki DNA metülatsiooninimustreid kui potentsiaal-
seid biomarkeri kandidaate. Selleks on kasutatud HM450K metülatsiooniandmeid
ning erinevaid arvutuslikke ja statistilisi meetodeid.
Väitekirja esimene osa keskendub DNA metülatsiooni analüüsile tervetes ja
haigetes kudedes. Selleks kasutati DNA metülatsiooniandmeid erinevatelt koos-
tööpartneritelt ning analüüsitulemused on avaldatud publikatsioonides I, II ja III.
Esimeses artiklis (publikatsioon I) näitasime, et metülatsioonimustrite alusel saab
kudesid klassifitseerida. Selles töös kasutasime näiteks andmete klasteranalüüsi,
lineaarset regressiooni, korrelatsioonianalüüsi ning integreerisime need andmed
ka geeniekspressiooniandmetega. Teises artiklis (publikatsioon II) oli peamiseks
analüütiliseks probleemiks tehnilise varieeruvuse körvaldamine, nimelt andmed
olid pärit erinevatest laboritest. Selle eemaldasime kasutades meetodit nimega
Empirical Bayes. Lisaks uurisime endometrioosiga seonduvaid metülatsioonipõhi-
seid biomarkereid kasutades esimeses publikatsioonist pärit lähenemist. Kolmanda
artikli (publikatsioon III) jaoks kohandasime varasemalt kasutatud metoodikaid
selleks, et identifitseerida endomeetriumi vastuvõtlikkusega seotud metülatsiooni-
mustreid. Lisaks rakendasime mitmeid erinevaid differentsiaalanalüüsimeetodeid
ning võtsime nende tulemuste ühisosa, et leida suurema usaldusväärsusega biomar-
kereid.
Tõõ teiseks eesmärgiks oli identifitseerida vähipatsientide elumusega seotud
biomarkereid. Selleks otstarbeks kasutasime andmeid TCGA (The Cancer Genome
Atlas) konsortsiumist. Antud tõõ tulemusena loodi intuitiivne veebirakendus (esita-
tud publikatsioonis IV), mis abistab teadlasi, kellel puudub vastav bioinformaatika-
ja statistikaalane kompetents. See rakendus võimaldab uurida, kuidas on DNA
metülatsioonimustrid seotud vähihaigete elumusega, visualiseerida metülatsiooni-
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mustreid, teha klasteranalüüsi ning kuvada olulisemaid biomarkereid iga vähitüübi
kohta.
Käesolev väitekiri on struktureeritud järgmiselt:
Esimeses osas tutvustatakse töö bioloogilist tausta (DNA metülatsiooni), võetakse
kokku metülatsiooni uurimise metoodikad ning rõhutatakse DNA metülatsiooni
mõju inimese tervisele. Lisaks antakse ülevaade kasutatud bioinformaatilistest mee-
toditest koos põgusa ülevaatega, milliseid probleeme nende meetoditega lahendati
(Lokk et al., 2014; Saare et al., 2016; Kukushkina et al., 2017; Modhukur et al.,
2017). Järgnevad neli peatükki võtavad kokku doktoritöös kasutatud publikatsioo-
nid, nendele järgnevad arutelu ning kokkuvõte. Samuti on lisatud eespool mainitud
neli publikatsiooni.
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